MarketCapExport financials
Anthem (ANTM)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Anthem Financial Ratios 2025-2006 | ANTM
Brief overview of Anthem's valuation multiples
Current figures are compared with the company's own five-year history for 2020–2024.
The latest available valuation ratios are P/E 17.22x (median 17.51x), P/S 0.58x (median 0.65x), P/B 2.49x (median 2.66x). The combined ratio level is close to the company's five-year norm at a -4.1% deviation. No clear premium or discount is visible.
At the current P/E, inverse earnings yield is 5.8%, a useful bridge between price and business earnings.
Current measures of operating quality are ROE 12.9%, ROA 4.7%, ROCE 16.4%. Return ratios are at workable levels. The business generates positive returns, though efficiency is not exceptional.
PEG is 0.46x. Price is low relative to embedded growth, though the ratio depends heavily on forecast quality.
Overall picture
Anthem's profile looks neutral, with price and fundamental efficiency broadly aligned.
Annual Financial Ratios Anthem
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
- | 17.2 | 17.5 | 18.1 | 18.3 | 17.4 | 14.0 | 20.4 | 16.2 | 16.5 | 13.3 | 14.1 | 10.3 | 7.5 | 8.3 | - | - | - | - | - |
P/S |
- | 0.6 | 0.6 | 0.7 | 0.8 | 0.7 | 0.6 | 0.8 | 0.7 | 0.5 | 0.4 | 0.5 | 0.4 | 0.3 | 0.4 | - | - | - | - | - |
EPS |
25.3 | 25.8 | 25.4 | 24.6 | 25.3 | 18.2 | 18.8 | 14.5 | 14.7 | 9.4 | 9.7 | 9.3 | 8.3 | 8.3 | 7.3 | 7.0 | 10.0 | 4.8 | 5.6 | - |
EV (Enterprise Value) |
68 B | 170 B | 168 B | 166 B | 169 B | 127 B | 108 B | 116 B | 103 B | 76.6 B | 70.6 B | 71.8 B | 59 B | 52.6 B | 48.4 B | 24.6 B | 22.4 B | 24.8 B | -2.77 B | -2.6 B |
EBITDA per Share |
39 | 39.9 | 43.4 | 41.5 | 36.4 | 30 | - | - | - | - | - | - | - | - | - | 10.2 | 9 | 8.57 | - | - |
EV/EBITDA |
7.8 | 18.4 | 16.4 | 16.6 | 19.2 | 241.7 | - | - | - | - | - | - | - | - | - | 5.9 | 5.2 | 5.6 | -23.0 | - |
PEG |
- | - | - | - | - | -3.33 | 0.46 | -7.01 | 0.27 | -3.71 | 5.94 | 1.09 | -4.0 | 0.64 | 4.06 | - | - | - | - | - |
P/B |
- | 2.5 | 2.7 | 2.9 | 3.1 | 2.4 | 2.1 | 2.7 | 2.4 | 1.6 | 1.5 | 1.5 | 1.0 | 0.8 | 0.9 | - | - | - | - | - |
P/CF |
- | 17.7 | 13.0 | 12.7 | 13.5 | 7.4 | 13.5 | 29.2 | 18.4 | 15.5 | 9.8 | 13.6 | 10.7 | 9.1 | 7.7 | - | - | - | - | - |
ROE % |
12.90 | 14.47 | 15.23 | 16.26 | 17.03 | 13.77 | 15.15 | 13.14 | 14.50 | 9.84 | 11.11 | 10.60 | 10.05 | 11.16 | 11.36 | 12.12 | 19.09 | 11.62 | 14.55 | - |
ROA % |
4.66 | 5.12 | 5.50 | 5.74 | 6.32 | 5.28 | 6.21 | 5.24 | 5.45 | 3.79 | 4.15 | 4.14 | 4.18 | 4.50 | 5.09 | 5.75 | 9.10 | 5.15 | - | - |
ROCE % |
16.41 | 19.03 | 21.62 | 22.85 | 20.90 | 19.16 | - | - | - | - | - | - | - | - | - | 17.12 | 16.81 | 20.29 | - | - |
Current Ratio |
1.6 | 1.5 | 1.6 | 1.5 | 1.6 | 1.6 | 1.4 | 1.3 | 1.4 | 1.3 | 1.3 | 1.4 | 1.4 | 1.5 | 1.3 | 1.9 | 1.9 | 1.8 | - | - |
DSO |
- | - | - | - | - | - | 37.0 | 36.9 | 35.6 | 36.8 | 33.8 | 35.8 | 27.1 | 28.7 | 26.8 | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios Anthem
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q3 | 2009-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
6.74 | 8.03 | - | 5.32 | 7.74 | 9.64 | - | 4.38 | 9.91 | 9.65 | - | 5.48 | 7.83 | 8.37 | - | 6.69 | 6.8 | 7.41 | - | 6.2 | 7.33 | 6.8 | 2.23 | 0.88 | 9.02 | 6.03 | 3.69 | 4.64 | 4.44 | 6.03 | 1.64 | 3.7 | 4.07 | 5.13 | 4.8 | 2.87 | 3.23 | 3.82 | 1.4 | 2.35 | 2.97 | 2.69 | 0.69 | 2.51 | 3.27 | 3.25 | 1.88 | 2.31 | 2.64 | 2.46 | 0.5 | 2.21 | 2.67 | 2.92 | 1.52 | 2.17 | 1.96 | 2.56 | 0.97 | 1.92 | 1.92 | 2.48 | 1.86 | 1.73 | 1.99 | 1.55 | 1.44 |
EBITDA per Share |
11.4 | 11.1 | - | 6.52 | 11.4 | 15.7 | - | 6.6 | 12.6 | 14.4 | - | 8.4 | 12 | 13.9 | - | 10.3 | 10.4 | 11.5 | - | 12.3 | 10.9 | 9.97 | - | 4.24 | 15.5 | 9.76 | - | 9.46 | 7.87 | 8.67 | - | 5.17 | 6.26 | 7.42 | - | 4.08 | 4.84 | 6.1 | - | 4.39 | 5.9 | 6.1 | - | 4.97 | 5.94 | 6.02 | - | 4.66 | 4.61 | 4.02 | - | 3.63 | 4.25 | 4.56 | - | 3.38 | 3.17 | 3.69 | - | 2.93 | 2.71 | 3.67 | 2.81 | 2.66 | 0.06 | 0.17 | 0.11 |
ROE % |
13.97 | 15.83 | 11.81 | 14.13 | 16.86 | 18.39 | 13.27 | 16.61 | 19.14 | 19.01 | 13.49 | 17.94 | 19.15 | 19.25 | 13.94 | 18.16 | 18.85 | 19.20 | 14.27 | 15.93 | 12.38 | 14.10 | 13.77 | 15.06 | 18.12 | 14.85 | 15.15 | 13.69 | 13.33 | 13.43 | 13.14 | 16.30 | 15.76 | 15.29 | 14.50 | 11.32 | 10.96 | 10.85 | 9.84 | 9.16 | 9.54 | 10.16 | 11.11 | 12.41 | 12.17 | 11.46 | 10.60 | 9.11 | 9.15 | 9.37 | 10.05 | 11.40 | 11.66 | 11.13 | 11.16 | 10.65 | 10.68 | 10.98 | 11.36 | 12.96 | 13.06 | 13.63 | 12.84 | 12.92 | 3.58 | 3.19 | 3.12 |
ROA % |
4.96 | 5.62 | 4.22 | 5.09 | 6.16 | 6.74 | 4.91 | 6.08 | 6.91 | 6.70 | 4.69 | 6.24 | 6.70 | 6.77 | 4.95 | 6.49 | 6.81 | 6.89 | 5.12 | 5.76 | 4.48 | 5.23 | 5.28 | 5.85 | 7.12 | 5.96 | 6.21 | 5.59 | 5.41 | 5.41 | 5.24 | 6.39 | 6.11 | 5.85 | 5.45 | 4.27 | 4.16 | 4.15 | 3.79 | 3.52 | 3.63 | 3.83 | 4.15 | 4.68 | 4.63 | 4.42 | 4.15 | 3.58 | 3.66 | 3.82 | 4.18 | 4.72 | 4.79 | 4.54 | 4.50 | 4.36 | 4.50 | 4.75 | 5.08 | 5.89 | 6.02 | 6.38 | 6.08 | 6.03 | 1.71 | 1.48 | 1.41 |
ROCE % |
17.17 | 20.68 | 15.93 | 19.14 | 22.73 | 24.59 | 17.15 | 21.71 | 25.36 | 26.38 | 18.97 | 25.22 | 27.20 | 27.07 | 19.51 | 25.26 | 24.96 | 24.79 | 18.06 | 18.66 | 23.04 | 23.71 | 17.33 | 22.15 | 26.06 | 22.06 | 15.45 | 19.82 | 20.47 | 22.50 | 16.38 | 20.09 | 20.34 | 20.86 | 14.32 | 18.61 | 20.88 | 22.51 | 16.53 | 21.83 | 24.10 | 24.97 | 18.72 | 23.63 | 23.37 | 21.42 | 14.57 | 18.61 | 18.64 | 19.08 | 14.46 | 18.68 | 18.81 | 18.96 | 13.48 | 17.65 | 17.50 | 19.13 | 14.04 | 18.31 | 18.58 | 5.80 | 4.27 | 4.45 | - | - | - |
Current Ratio |
1.6 | 1.5 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.5 | 1.5 | 1.5 | 1.6 | 1.5 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 | 1.8 | 1.8 | 1.8 | 1.8 | 1.9 | 1.9 | 1.9 | 1.9 | 1.8 |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company Anthem, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Health care industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Molina Healthcare
MOH
|
$ 207.36 | 1.67 % | $ 10.9 B |  USA |
 |
Centene Corporation
CNC
|
$ 69.16 | 0.5 % | $ 34.1 B | USA |
 |
UnitedHealth Group Inc.
UNH
|
$ 401.43 | 2.77 % | $ 364 B | USA |
 |
Humana
HUM
|
$ 413.16 | 1.03 % | $ 49.8 B | USA |
 |
NovoCure Limited
NVCR
|
$ 14.07 | 4.12 % | $ 1.57 B |  Jersey |
 |
Triple-S Management Corporation
GTS
|
- | 0.28 % | $ 847 M | USA |
 |
Cigna Corporation
CI
|
$ 302.3 | 1.17 % | $ 79.6 B | USA |
 |
CVS Health Corporation
CVS
|
$ 92.36 | 0.33 % | $ 117 B | USA |
 |
Magellan Health, Inc.
MGLN
|
- | -0.19 % | $ 2.49 B | USA |